View Report
September 13, 2024
Measured Result
9.39 mg
93.90% of label claim
Stealth Labs
Stealth Labs
Latest Laboratory Result 9.39 mg September 13, 2024 · 93.90% of label claim View
Cagrilintide 10 mg
Product Information Compound Details
Active Substance Cagrilintide Long-acting amylin analogue
10 mg/vialStrength 10 mg/vial
Package 1 Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Stealth Labs
Packaging Notice Shipped Without Product Label This Stealth Labs product is supplied in an unlabeled vial.
Shipping :
International
U.S. Domestic
Out of stock
Product Overview
Cagrilintide 10 mg by Stealth Labs
Cagrilintide 10 mg is a lyophilized research peptide manufactured by Stealth Labs, supplied as 10 mg/vial of cagrilintide in a 2 mL vial.
Cagrilintide Lyophilized Powder
Cagrilintide 10 mg is a long-acting amylin analogue peptide developed for investigation in weight management and type 2 diabetes. It is not FDA-approved for any indication as of 2026 and is available only within clinical trials.
Cagrilintide was engineered to overcome the limitations of pramlintide, the only previously FDA-approved amylin-based therapy, which requires three injections daily due to its short half-life. Cagrilintide is a non-fibrillating amylin analogue with a half-life of approximately 159–195 hours, allowing for once-weekly subcutaneous administration. As a dual amylin and calcitonin receptor agonist, cagrilintide binds to AMY1R, AMY2R, AMY3R, and CTR, with structural studies revealing an amylin-like binding mode that induces distinct conformational dynamics at calcitonin-family receptors.
In clinical trials, cagrilintide has been studied both as a monotherapy and in combination with semaglutide (CagriSema). A 2021 Phase 2 dose-finding trial reported approximately 10.8% weight loss at 4.5 mg over 26 weeks as monotherapy. The REDEFINE Phase 3 program for the fixed combination CagriSema reported 20.4% weight loss at 68 weeks in adults with obesity without diabetes, and a New Drug Application was submitted to the FDA in December 2025. However, cagrilintide as a standalone agent remains investigational, and Novo Nordisk has not announced plans to seek approval for monotherapy.
Key Benefits of Cagrilintide 10 mg
- Long-acting amylin analogue with extended half-life of 159–195 hours
- Dual amylin and calcitonin receptor agonist mechanism
- Lyophilized powder format for research applications
- 10 mg/vial concentration in a 2 mL vial
- Manufactured by Stealth Labs with published laboratory verification
Formulation
Lyophilized Powder
Cagrilintide 10 mg is supplied as a lyophilized (freeze-dried) powder in a 2 mL glass vial. Reconstitution with an appropriate solvent is required before use in research applications.
Product Profile
Cagrilintide Profile
Cagrilintide is a long-acting amylin analogue under clinical investigation for weight management and metabolic control.
Long-Acting Amylin Analogue
Endogenous amylin is a pancreatic hormone co-secreted with insulin that reduces eating and inhibits postprandial glucagon secretion. Its primary site of action is the area postrema in the hindbrain, from which signals propagate to the nucleus of the solitary tract and lateral parabrachial nucleus. Amylin binds to heteromeric receptor complexes composed of the calcitonin receptor and specific receptor activity-modifying proteins (RAMPs 1–3), forming three distinct receptor subtypes: AMY1R, AMY2R, and AMY3R.
Cagrilintide was developed through structure-activity relationship studies with the aim of generating a long-acting non-fibrillating amylin analogue with retained affinity for AMY3R. It is N-terminally acylated with a γGlu linker and a C20 fatty diacid moiety, which contributes to its extended half-life. Pharmacokinetic analysis in combination with semaglutide 2.4 mg showed cagrilintide doses of 0.16–4.5 mg had a half-life of 159–195 hours, with median time to maximum concentration of 24–72 hours.
In vivo studies demonstrate that cagrilintide reduces food intake and body weight by reducing relative fat mass while maintaining relative lean mass. These effects are accompanied by activation of neurons in the area postrema via amylin receptor subtypes 1 and 3.
Research Status
Investigational Only
As of 2026, cagrilintide is not FDA-approved for any indication and has never been approved for compounding under Section 503A or 503B. It has not appeared on any FDA bulk drug substance list. Cagrilintide is available only within the context of clinical trials and is not obtainable through licensed compounding pharmacies or by standard prescription.
Cagrilintide 10 mg vs Other Stealth Labs Peptides
Stealth Labs offers Survodutide and Mazdutide as other research peptides commonly referenced in metabolic research contexts. Unlike cagrilintide, which targets amylin and calcitonin receptors, survodutide and mazdutide are dual GLP-1/glucagon receptor agonists.
Compared to TB 500, which is a thymosin beta-4 fragment studied for tissue healing, cagrilintide is a metabolic peptide with a distinct mechanism of action targeting appetite regulation and energy homeostasis. Both are lyophilized powders requiring reconstitution, and neither is FDA-approved for human use.
Laboratory Testing
Cagrilintide 10 mg Lab Reports
Published laboratory reports for Cagrilintide 10 mg are shown below with the test date, measured concentration and percentage of the product's 10 mg/vial label claim.
View Report
Laboratory results apply to the specific tested sample represented in each published report and should not be interpreted as a measurement of every vial or production batch.
Dosage & Usage
Cagrilintide 10 mg Dosage & Usage
The information below is provided for educational reference only. Cagrilintide is not FDA-approved for any indication and is available only within clinical trials. No human dosing information is established for non-clinical settings, and non-medical use falls outside any approved indication.
Clinical Trial Reference Ranges
In clinical trials, cagrilintide has been studied at doses ranging from 0.16 mg to 4.5 mg as monotherapy, with 2.4 mg and 4.5 mg being the most commonly referenced doses for weight management investigation. Cagrilintide is administered as a once-weekly subcutaneous injection. Common reference ranges for cagrilintide in non-medical contexts are not well characterized in publicly available bodybuilding resources, as the compound is not FDA-approved and remains investigational only.
| Use Case | Clinical Trial Reference Range | Frequency |
|---|---|---|
| Phase 2 monotherapy (investigational) | 0.16–4.5 mg per week | Once weekly |
| Phase 3 combination (CagriSema) | 2.4 mg cagrilintide + 2.4 mg semaglutide | Once weekly |
| Non-medical research | Not established | Not applicable |
Reconstitution & Handling
Cagrilintide is supplied as a lyophilized powder requiring reconstitution with an appropriate solvent such as bacteriostatic water or sterile saline. Once reconstituted, peptide solutions are more susceptible to degradation and should be stored refrigerated at 2–8°C. Avoid repeated freeze-thaw cycles, which can degrade the peptide and potentially increase immunogenicity risk.
Reconstitution should be performed gently by swirling rather than shaking to prevent denaturation or aggregation. A cloudy solution or visible particles may indicate incomplete dissolution, aggregation, or contamination and should not be used.
Managing Research Risks
Cagrilintide has been studied in clinical trials with a safety profile generally consistent with the amylin analogue and GLP-1 receptor agonist classes. Adverse events in trials were most commonly gastrointestinal, including nausea, vomiting, and diarrhea, though cagrilintide monotherapy has been noted to have less vomiting than GLP-1 receptor agonists in network meta-analysis. Injection-site reactions were more common with CagriSema compared to semaglutide alone.
Because cagrilintide is investigational only, no long-term safety data exist outside clinical trial settings. Products sold online under the name cagrilintide through research compound vendors are not FDA-regulated, have no verified manufacturing standards, and carry unknown contamination, dosing, and safety risks.
Post-Cycle Considerations
Cagrilintide is not a hormone and does not suppress endogenous testosterone production. No post-cycle therapy is applicable or necessary for cagrilintide alone. If cagrilintide is referenced alongside anabolic compounds in non-medical contexts, any PCT protocol would be determined by the other compounds, not by cagrilintide.
Important
Individual Response Varies
No human clinical data exists to support any specific dosing strategy for cagrilintide in non-clinical settings. The information above is for educational reference only and does not constitute medical advice. Cagrilintide is not FDA-approved for any indication.
Safety & Information
Cagrilintide Safety Information
Cagrilintide is not FDA-approved for any indication and is available only within clinical trials. Its safety profile outside trial settings is not characterized.
Important Safety Information
As of 2026, cagrilintide is not FDA-approved for any indication. It has never been approved for compounding under Section 503A or 503B and has not appeared on any FDA bulk drug substance list. Cagrilintide is available only within the context of clinical trials and is not obtainable through licensed compounding pharmacies or by standard prescription.
Novo Nordisk has not announced plans to seek FDA approval for cagrilintide as a monotherapy. The regulatory pathway being pursued is for CagriSema, a fixed co-administration regimen of cagrilintide 2.4 mg and semaglutide 2.4 mg. A New Drug Application for CagriSema was submitted to the FDA in December 2025.
Important
Not FDA-Approved
Cagrilintide is investigational and not approved for human use. Products sold online under the name cagrilintide through research compound vendors are not FDA-regulated, have no verified manufacturing standards, and carry unknown contamination, dosing, and safety risks.
Potential Adverse Effects
In clinical trials, adverse events with cagrilintide were most commonly gastrointestinal, including nausea, vomiting, and diarrhea. Most adverse events were mild to moderate in severity. Network meta-analysis found that cagrilintide ranked best for serious adverse events and allergic reactions compared to semaglutide, while CagriSema exhibited the most favorable gastrointestinal tolerability profile.
Injection-site reactions were more common with CagriSema compared to semaglutide alone. Because cagrilintide remains investigational, no long-term safety data exist outside clinical trial settings, and cardiovascular outcomes data for cagrilintide are not yet available.
Conditions Requiring Medical Evaluation
As cagrilintide is not approved for any indication, there are no established contraindications in non-clinical settings. Clinical trial exclusion criteria have included history of type 1 or type 2 diabetes in some weight management studies, pregnancy or breastfeeding, and treatment with GLP-1 receptor agonist medications within specified washout periods.
Monitoring During Research Use
No monitoring parameters have been established for cagrilintide outside clinical trial settings. Laboratory testing of the product itself, such as the published potency report shown in the Lab Reports tab, is separate from any clinical monitoring. Product testing does not assess individual health status or suitability for use.
Product Care
Storage & Handling
Lyophilized cagrilintide should be stored at -20°C or below for maximal stability, protected from moisture and light. Allow the vial to warm to room temperature before opening to prevent condensation.
Reconstituted cagrilintide should be stored refrigerated at 2–8°C and used within a reasonable timeframe. Avoid repeated freeze-thaw cycles, which can degrade the peptide. Keep all research peptides out of the reach of children.
Further Safety Information
Shipping & Authenticity
Shipping & Product Authenticity
Cagrilintide 10 mg is supplied through the official Stealth Labs distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
USA Domestic
3–5 business days
International
10–15 business days
Order Processing
24–48 business hours
Tracking
Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official Stealth Labs distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your Cagrilintide 10 mg product, use the security code on the vial label and cross-check it on the Stealth Labs official site. Official Stealth Labs presentation, batch-linked lab proof, and original packaging help reinforce product legitimacy and buyer confidence.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Storage
Cagrilintide 10 mg Storage
Proper storage conditions help preserve peptide stability and overall product integrity throughout shelf life.
Recommended Conditions
Lyophilized cagrilintide should be stored at -20°C or below for maximal stability, protected from moisture and light. Short-term storage at room temperature is relatively stable for weeks, but long-term storage requires freezing. Allow the vial to warm to room temperature before opening to prevent condensation.
Reconstituted cagrilintide should be stored refrigerated at 2–8°C and used within a reasonable timeframe. Avoid repeated freeze-thaw cycles, which can degrade the peptide. Inspect the solution before use and do not use if it appears cloudy, discolored, or contains particulate matter.
Quick Reference
Do & Don't
- Do store lyophilized powder at -20°C or below
- Do refrigerate reconstituted solution at 2–8°C
- Do allow vial to warm before opening
- Don't freeze reconstituted solution repeatedly
- Don't expose to excessive heat, light, or moisture
- Don't use if solution looks cloudy or contains particles
Frequently Asked Questions
Cagrilintide 10 mg FAQ
Answers to common questions about Cagrilintide 10 mg, its research status, clinical trial data, and laboratory testing.
What is Cagrilintide 10 mg used for?
Cagrilintide 10 mg is a lyophilized research peptide sold for laboratory use only. In clinical trials, cagrilintide has been investigated as a monotherapy and in combination with semaglutide for weight management and type 2 diabetes. It is not FDA-approved for any indication and is available only within clinical trials.
How often should Cagrilintide 10 mg be used?
In clinical trials, cagrilintide is administered as a once-weekly subcutaneous injection. Doses studied have ranged from 0.16 mg to 4.5 mg as monotherapy, with 2.4 mg being the dose used in the CagriSema combination. No dosing recommendation can be made for non-clinical settings, as cagrilintide is not FDA-approved.
Does Cagrilintide 10 mg require PCT?
Cagrilintide is a peptide, not a hormone, and does not suppress endogenous testosterone production. No post-cycle therapy is applicable or necessary for cagrilintide alone. If cagrilintide is referenced alongside anabolic compounds in non-medical contexts, any PCT protocol would be determined by the other compounds, not by cagrilintide.
What does cagrilintide do?
Cagrilintide is a long-acting amylin analogue that acts as a dual amylin and calcitonin receptor agonist. It binds to AMY1R, AMY2R, AMY3R, and CTR, with primary action at the area postrema in the hindbrain to reduce food intake and body weight. In animal studies, it reduces relative fat mass while maintaining relative lean mass.
How long does cagrilintide take to work?
Cagrilintide has a half-life of 159–195 hours, with median time to maximum concentration of 24–72 hours after subcutaneous administration. In clinical trials, weight loss effects were observed over treatment periods of 20 to 68 weeks. The time required to notice effects depends on the individual and the specific outcome being evaluated.
Is cagrilintide the best weight management peptide?
There is no single agent that is universally best. Cagrilintide as a monotherapy achieved approximately 10.8% weight loss at 4.5 mg over 26 weeks in Phase 2 trials, while the CagriSema combination achieved 20.4% weight loss at 68 weeks in Phase 3 trials. Cagrilintide is investigational only, and non-medical use falls outside approved indications.
What is the difference between cagrilintide and semaglutide?
Cagrilintide is an amylin analogue that targets amylin and calcitonin receptors, while semaglutide is a GLP-1 receptor agonist. The two mechanisms are complementary, and the combination CagriSema has shown superior weight loss compared to semaglutide alone. Cagrilintide remains investigational, while semaglutide is FDA-approved.
What is the difference between cagrilintide and tirzepatide?
Cagrilintide is an amylin analogue, while tirzepatide is a dual GIP/GLP-1 receptor agonist. In a Phase 3 trial, CagriSema did not meet the primary endpoint of showing non-inferiority on weight loss compared to tirzepatide 15 mg at 84 weeks, though it achieved 23% weight loss. Both are distinct compounds with different mechanisms of action.
Is 10 mg of Cagrilintide a lot?
A milligram amount cannot be classified as appropriate or excessive because cagrilintide is not FDA-approved and no non-clinical dosing information exists. It is also important to distinguish a total vial content from a dose. Cagrilintide 10 mg indicates the total peptide content per vial; that quantity does not by itself specify how much should be used in any research application.
What strength is Cagrilintide 10 mg?
Cagrilintide 10 mg is labeled at 10 mg of cagrilintide per vial. It is supplied as a lyophilized powder in a 2 mL vial.
Is Cagrilintide 10 mg lab tested?
Yes. A published laboratory report dated September 13, 2024 measured Cagrilintide 10 mg at 9.39 mg, equivalent to 93.90% of its 10 mg/vial label claim. The complete report can be viewed in the Lab Reports tab. Laboratory results apply to the tested sample represented by the individual report.
Can Cagrilintide 10 mg be stacked with other compounds?
Cagrilintide is not FDA-approved, and no clinical data exists to support any combination with other compounds outside of clinical trials. In clinical trials, cagrilintide has been studied in combination with semaglutide as CagriSema. Stealth Labs offers Survodutide and Mazdutide as other research peptides, but combinations with cagrilintide lack clinical validation.
Related Offers
Lab Tested
Shipped USA Domestic
-40% OFF
Dragon Pharma, Europe
Product Information Compound Details
Active Substance Cagrilintide Acetate Long-acting amylin analogue
10 mg/vialStrength 10 mg/vial
Package 2 mL Vial Lyophilized powder
Form Lyophilized Powder
Drug Class Research Peptide
Manufacturer Dragon Pharma
Half-Life Approximately 159–195 Hours
$96.00
$160.00
Lab Tested
Shipped International
-40% OFF
Peptide Hubs
Product Information Compound Details
Active Substance Cagrilintide Long-acting amylin analog
10 mg/vialStrength 10 mg/vial
Package 1 Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Peptide Hubs
$54.00
$90.00
Shipped International
Bharat Serums And Vaccines Ltd, India
Drug Class: Natural Hormone
Active Substance: Pre-mixed Human Chorionic Gonadotropin 10000IU
Active Life: -
Average Dose: -
Liver Toxicity: No
Aromatization Rate: No
Anabolic Rate: Not a steroid
Androgenic Rate: Not a steroid
This Price Is Per amp (1 mL Each)
$90.00
Shipped International
Sun Pharma, India
Drug Class: Natural Hormone
Active Substance: Human Chorionic Gonadotropin 5000IU
Active Life: -
Average Dose: -
Liver Toxicity: No
Aromatization Rate: No
Anabolic Rate: Not a steroid
Androgenic Rate: Not a steroid
This Price Is Per amp (1 mL Each)
$70.00
Shipped International
Bharat Serums And Vaccines Ltd, India
Drug Class: Natural Hormone
Active Substance: Pre-mixed Human Chorionic Gonadotropin 5000IU
Active Life: -
Average Dose: -
Liver Toxicity: No
Aromatization Rate: No
Anabolic Rate: Not a steroid
Androgenic Rate: Not a steroid
This Price Is Per amp (1 mL Each)
$70.00
Lab Tested
Domestic & International
Dragon Pharma, Europe
Product Information Compound Details
Active Substance Human Chorionic Gonadotropin (HCG) Chorionic Gonadotropin for Injection
2,500 or 5,000 IU/vialVial Strength 2,500 IU or 5,000 IU
Package 1 × 2 mL Vial
Form Lyophilized Powder
Drug Class Gonadotropin
Hormone Type Glycoprotein Hormone
Manufacturer Dragon Pharma
$75.00